Edition:
United Kingdom

Profile: Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

16.88EUR
17 May 2019
Change (% chg)

€-0.23 (-1.34%)
Prev Close
€17.11
Open
€16.72
Day's High
€16.98
Day's Low
€16.55
Volume
42,544
Avg. Vol
56,321
52-wk High
€27.26
52-wk Low
€13.51

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Company Address

Cellectis SA

8 rue de la Croix-Jarry
PARIS     75013
P: +331.81691600
F: +331.81691606

Company Web Links